• Juan-Manuel Sancho, Belén Navarro, Joan Alfons Soler Campos, Jaime Pérez de Oteyza, Cristina de Barrenetxea Lekue, Marco Bregni, Silvina Grasso Cicala, Mario Spione, Cristina Mombiedro, Begoña Soler, and Pier Luigi Zinzani.
• Clinical Haematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain.
• Eur. J. Haematol. 2020 May 1; 104 (5): 499-508.

Background And ObjectiveFew treatment options exist for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who fail first- and second-line therapies. Pixantrone is a novel aza-anthracenedione agent with reduced potential for cardiotoxicity but maintained anti-tumour activity relative to anthracyclines. The current retrospective, observational, real-life study was undertaken in 79 patients who received pixantrone monotherapy for multiply R/R aggressive B-cell NHL in Spain and Italy.ResultsBefore pixantrone, patients had received a median of 3 prior therapies and 84.6% of them were refractory to the last regimen. Median progression-free survival (mPFS) was 2.8 months (95% confidence interval [CI] 2.1-3.6) and median overall survival (mOS) was 4.0 months (95%CI 5.6-7.9), with an objective response rate (ORR) of 29% (complete remission [CR]: 13.2%, partial remission [PR]: 15.2%). Patients receiving ≥2 cycles of pixantrone showed mPFS and mOS of 3.1 and 6.0 months, respectively, and an ORR of 36.8% (CR: 17.5%, PR: 19.3%). Overall, 63.3% of patients reported ≥1 adverse event (AE), most commonly haematological AEs. One patient developed grade 2 sinus tachycardia.ConclusionPixantrone was effective and well tolerated in a real-world population of multiply R/R patients with aggressive B-cell NHL, many of whom had very poor prognostic factors.© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

33 keywords...

hide…